Research article · 31 Aug 2022
Review articlePublished 2014
Roles of Serine Protease Inhibitor Kazal type 1 (SPINK1) in Prostate Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Altered genes that play a driving role in cancer development can often serve as specific diagnostic markers, criteria of molecular classification and therefore potential therapeutic targets. Serine protease inhibitor Kazal type 1 (SPINK1), also known as pancreatic secretory trypsin inhibitor or tumor-associated trypsin inhibitor, encodes a 56 amino acid secreted peptide, and its normal function is thought to be the inhibition of serine proteases such as trypsin. Recent studies have indicated marked overexpression of SPINK1 defines an aggressive molecular subtype of ETS (erythroblastosis virus E26 transformation-specific) fusion-negative prostate cancer ((PCa) patients. SPINK1 may act as an autocrine growth factor and promotes PCa growth and invasion. Most recently, we suggested that SPINK1 induces epithelial-mesenchymal transition (EMT) through EGFR signaling pathway in PCa. The association between SPINK1 overexpression and poor prognosis in PCa has been reported. Notably, SPINK1 might be a novel extracellular therapeutic target in a subset of high-grade PCa patients. In this review, we will summarize the current understanding of SPINK1 involving its role in PCa biology, association with prognosis as well as perspective in therapy from the pathologist's point of view.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 5 Dec 2016
Computer-aided design, efficient synthesis and mechanistic studies of serine protease covalent inhibitors
Conference abstract · 8 Dec 2014
Serine protease inhibitor (serpin) reactive site loop peptides as therapy for acute viral sepsis with inflammatory vascuits and hemorrhage
Conference abstract · 7 Dec 2015
Targeting viral serine proteases with phosphonic inhibitors
Research article · 28 Aug 2020
Predicted Treatment for COVID-19 Infection: Design, Docking Study and ADMET Prediction of Novel Small Molecules as Serine Protease Inhibitors
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Chengwu Shen”
- BylineArticles whose byline prints “Jing Zhang”
- BylineArticles whose byline prints “Mei Qi”
- BylineArticles whose byline prints “Yannicca WYChang”
- BylineArticles whose byline prints “Bo Han”

